Novartis Ag

Yasser Khder

Stefan Ewert

Alexander W Koch

Samu Melkko

Ulrich Hassiepen

Jorg Eder

Nikolaus Schiering

Lorenz Mayr

The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof

The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI ('Factor XIa'), and pharmaceutical compositions and methods of treatment comprising the same.

Factor XI antibodies and methods of use

Growing community of inventors

Hesingue, France

Yasser Khder